(-1.09%) 5 060.42 points
(-1.22%) 37 917 points
(-1.32%) 15 772 points
(-1.02%) $81.79
(-2.02%) $1.989
(-2.26%) $2 304.50
(-3.63%) $26.66
(-1.54%) $946.70
(0.45%) $0.937
(0.98%) $11.09
(0.48%) $0.800
(0.19%) $93.48
Live Chart Being Loaded With Signals
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States...
Stats | |
---|---|
今日成交量 | 2.01M |
平均成交量 | 1.27M |
市值 | 3.42B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -4.01 |
ATR14 | HKD0.0330 (0.57%) |
音量 相关性
CARsgen Therapeutics 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
CARsgen Therapeutics 相关性 - 货币/商品
CARsgen Therapeutics 财务报表
Annual | 2023 |
营收: | HKD0 |
毛利润: | HKD0 (0.00 %) |
EPS: | HKD-1.340 |
FY | 2023 |
营收: | HKD0 |
毛利润: | HKD0 (0.00 %) |
EPS: | HKD-1.340 |
FY | 2022 |
营收: | HKD0 |
毛利润: | HKD0 (0.00 %) |
EPS: | HKD-1.620 |
FY | 2021 |
营收: | HKD25.81M |
毛利润: | HKD25.81M (100.00 %) |
EPS: | HKD-8.36 |
Financial Reports:
No articles found.
CARsgen Therapeutics
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。